Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 213
Filter
1.
Vet Pathol ; 44(1): 1-14, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17197619

ABSTRACT

Thyroid carcinomas are the most common endocrine neoplasms in humans, with a globally increasing incidence. Thyroid follicular cells and neuroendocrine (parafollicular) C cells are each susceptible to neoplastic transformation, resulting in thyroid cancers of differing phenotypes with unique associated genetic mutations and clinical outcomes. Over the past 15 years, several sophisticated genetically engineered mouse models of thyroid cancer have been created to further our understanding of the genetic events leading to thyroid carcinogenesis in vivo. The most significant mouse models of papillary, follicular, anaplastic, and medullary thyroid carcinoma are highlighted, with particular emphasis on the relationship between the relevant oncogenes in these models and genetic events in the naturally occurring human disease. Limitations of each model are presented, and the need for additional models to better recapitulate certain aspects of the human disease is discussed.


Subject(s)
Disease Models, Animal , Thyroid Neoplasms/genetics , Animals , Animals, Genetically Modified , Female , Humans , Male , Mice , Oncogenes , Thyroid Neoplasms/pathology
2.
Hum Exp Toxicol ; 24(12): 643-54, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16408618

ABSTRACT

The carcinogenic potential of nelfinavir mesylate (nelfinavir) was evaluated in a 2-year oral (gavage) study on Sprague-Dawley rats at dose levels of 0 (control), 0 (vehicle control), 100, 300 and 1000 mg/kg per day. At the end of the treatment, increased incidences of thyroid follicular cell hyperplasia and neoplasms were observed at 300 (males) and 1000 mg/kg per day (both sexes). There were no other treatment-related effects and no tumors at other sites. Results from previous studies indicated a number of effects in the liver and thyroid, as well as metabolic profiles that suggested nelfinavir might cause thyroid hyperplasia/neoplasia secondary to hormone imbalance by altering thyroid hormone disposition. To investigate this hypothesis, the effects of nelfinavir on gene expression in rat hepatocytes and liver slices (in vitro), thyroxine plasma clearance, and thyroid gland function were evaluated. Compared to controls, gene expression analyses demonstrated an increased expression of glucuronyltransferase (UDPGT) and CYP450 3A1 in nelfinavir-treated rat hepatocytes and liver slices. In rats treated with nelfinavir (1000 mg/kg per day) for 4 weeks, liver weights and centrilobular hepatocellular hypertrophy were increased and minimal to mild diffuse thyroid follicular cell hypertrophy and follicular cell hyperplasia were evident in the thyroid gland. Thyroid-stimulating hormone (TSH) levels were significantly increased (three-fold), while tri-iodothyronine (T3)/tetra-iodothyronine (T4) and reverse T3(rT3) levels were unchanged, indicating that a compensated state to maintain homeostasis of T3/T4 had been achieved. Plasma 125I-thyroxine clearance was increased and the plasma thyroxine AUC0-48 was decreased (24%) compared to control. In conclusion, these data indicate that thyroid neoplasms observed in the nelfinavir-treated rats were secondary to thyroid hormone imbalance. Increased thyroxine clearance contributes to the effects of nelfinavir on thyroid gland function and is probably a result of UDPGT induction that leads to elevated TSH levels in the rat and eventual thyroid neoplasia. These results are consistent with a well-recognized rat-specific mechanism for thyroid neoplasms.


Subject(s)
Adenocarcinoma, Follicular/chemically induced , HIV Protease Inhibitors/toxicity , Nelfinavir/toxicity , Thyroid Gland/drug effects , Thyroid Neoplasms/chemically induced , Adenocarcinoma, Follicular/metabolism , Adenocarcinoma, Follicular/pathology , Administration, Oral , Animals , Aryl Hydrocarbon Hydroxylases/genetics , Aryl Hydrocarbon Hydroxylases/metabolism , Carcinogenicity Tests , Cell Survival/drug effects , Cells, Cultured , Cytochrome P-450 CYP3A , Dose-Response Relationship, Drug , Female , Gene Expression/drug effects , Glucuronosyltransferase/genetics , Glucuronosyltransferase/metabolism , HIV Protease Inhibitors/pharmacokinetics , Hepatocytes/drug effects , Hepatocytes/enzymology , Hepatocytes/pathology , Hyperplasia/chemically induced , Hyperplasia/metabolism , Hyperplasia/pathology , Longevity/drug effects , Male , Nelfinavir/pharmacokinetics , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Species Specificity , Thyroid Gland/metabolism , Thyroid Gland/pathology , Thyroid Hormones/blood , Thyroid Neoplasms/metabolism , Thyroid Neoplasms/pathology , Thyroxine/blood , Thyroxine/pharmacokinetics
3.
Vet Pathol ; 41(4): 446-9, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15232151

ABSTRACT

Adrenocortical neoplasms are a common cause of morbidity in neutered ferrets. Recently we showed that gonadectomized DBA/2J mice develop adrenocortical tumors that express transcription factor GATA-4. Therefore, we screened archival specimens of adrenocortical neoplasms from neutered ferrets to determine whether GATA-4 could be used as a tumor marker in this species. Nuclear immunoreactivity for GATA-4 was evident in 19/22 (86%) of ferret adrenocortical carcinomas and was prominent in areas exhibiting myxoid differentiation. Normal adrenocortical cells lacked GATA-4 expression. Two other markers of adrenocortical tumors in gonadectomized mice, inhibin-alpha and luteinizing hormone receptor, were coexpressed with GATA-4 in some of the ferret tumors. No GATA-4 expression was observed in three cases of nodular hyperplasia, but patches of anaplastic cells expressing GATA-4 were evident in 7/14 (50%) of tumors classified as adenomas. We conclude that GATA-4 can function as a marker of anaplasia in ferret adrenocortical tumors.


Subject(s)
Adrenal Cortex Neoplasms/veterinary , Adrenocortical Carcinoma/veterinary , Biomarkers, Tumor/metabolism , DNA-Binding Proteins/metabolism , Ferrets , Transcription Factors/metabolism , Adrenal Cortex Neoplasms/metabolism , Adrenal Cortex Neoplasms/pathology , Adrenocortical Carcinoma/metabolism , Adrenocortical Carcinoma/pathology , Animals , GATA4 Transcription Factor , Immunohistochemistry/veterinary , Inhibins/metabolism , Receptors, LH/metabolism
4.
J Steroid Biochem Mol Biol ; 89-90(1-5): 409-12, 2004 May.
Article in English | MEDLINE | ID: mdl-15225811

ABSTRACT

The aim of this study was to investigate effects of 1,25(OH)(2)D(3) (calcitriol), 25OHD(3), and EB1089 on cell growth and on Vitamin D receptor (VDR) mRNA and 1alpha-hydroxylase (1alpha-OHase) mRNA expression in normal canine prostatic primary cultures. Canine prostatic epithelial cells were isolated, cultured, and treated with vehicle (ethanol), calcitriol, 25OHD(3), and EB1089 at 10(-9) and 10(-7)M. The VDR was present in epithelial and stromal cells of the canine prostate gland. 1,25(OH)(2)D(3), 25OHD(3), and EB1089 inhibited epithelial cell growth at 10(-7)M compared to vehicle-treated controls [calcitriol (P < 0.01), EB1089 (P < 0.01), and 25OHD(3) (P < 0.05)]. Epithelial cells treated with calcitriol and EB1089 at 10(-7)M had slightly increased VDR mRNA expression (0.2-0.3-fold) at 6 and 12h compared to controls. There was no difference in 1alpha-OHase mRNA expression in epithelial cells treated with these three compounds. 1,25(OH)(2)D(3) and its analogs may be effective antiproliferative agents of epithelial cells in certain types of prostate cancer.


Subject(s)
Calcifediol/pharmacology , Calcitriol/pharmacology , Cell Division/drug effects , Prostate/drug effects , RNA, Messenger/genetics , Receptors, Calcitriol/genetics , Steroid Hydroxylases/genetics , Animals , Cells, Cultured , Dogs , Immunohistochemistry , Male , Prostate/cytology , Prostate/enzymology , Prostate/metabolism , RNA, Messenger/metabolism
5.
J Mol Endocrinol ; 31(3): 609-20, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14664720

ABSTRACT

Parathyroid hormone (PTH) is secreted by the chief cells of the parathyroid gland in response to changes in ionized calcium (Ca(2+)) concentrations. In this study, we measured PTH secretion, and PTH mRNA and calcium-sensing receptor (CaR) mRNA expression by equine parathyroid chief cells in vitro. We also evaluated the effects of interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF)-alpha on PTH secretion, and PTH and CaR mRNA expression. The relationship between PTH and Ca(2+) was inversely related. PTH secretion decreased from 100% (day 0) to 13% (day 30). PTH mRNA expression declined from 100% (day 0) to 25% (day 30). CaR mRNA decreased from 100% (day 0) to 16% (day 30). Chief cells exposed to high (2.0 mM) Ca(2+) concentrations had a lower PTH mRNA expression compared with low Ca(2+) concentrations. Ca(2+) concentrations had no effect on CaR mRNA expression. The inhibitory effect of high Ca(2+) concentrations on PTH secretion also declined over time. After day 10, there was no significant difference in PTH secretion between low and high Ca(2+ )concentrations. IL-1beta decreased both PTH secretion (75%) and PTH mRNA expression (73%), and resulted in a significant overexpression of CaR mRNA (up to 142%). The effects of IL-1beta were blocked by an IL-1 receptor antagonist. IL-1beta decreased the Ca(2+) set-point from 1.4 mM to 1.2 mM. IL-6 decreased PTH secretion (74%), but had no effect on PTH and CaR mRNA expression. TNF-alpha had no effect on PTH secretion, and PTH and CaR mRNA expression. In summary, the decreased responsiveness of parathyroid cells to Ca(2+) from 0 to 30 days can be explained, in part, by the reduced CaR expression. IL-1beta and IL-6 but not TNF-alpha affected parathyroid function in vitro and may be important in influencing PTH secretion in the septic horse.


Subject(s)
Interleukin-1/pharmacology , Interleukin-6/pharmacology , Parathyroid Glands/metabolism , Parathyroid Hormone/metabolism , Receptors, Calcium-Sensing/metabolism , Animals , Calcium/metabolism , Cells, Cultured , Horses/metabolism , Tumor Necrosis Factor-alpha/pharmacology
6.
Vet Pathol ; 40(2): 136-42, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12637752

ABSTRACT

A total of 15 adrenocortical carcinomas with myxoid differentiation from 15 ferrets were evaluated in this retrospective study. Six of these ferrets (40%) either were euthanatized or died due to invasive and/or metastatic disease. The myxoid component was a variable part (between 5% and 95%) of the adrenal cortical neoplasm and consisted of sheets and cords of small, polygonal neoplastic cells that formed lumenlike spaces. Such spaces contained a variable amount of alcian blue (pH 2.5)-positive mucinous product (i.e., acidic mucopolysaccharides). Neoplastic cells were negative for the argentaffin reaction, but immunohistochemically they were strongly positive for vimentin and alpha-inhibin and lightly positive for synaptophysin. Proliferating cell nuclear antigen (PCNA)-labeling indices (LI) of adrenal cortical neoplastic cells within the myxoid component of the neoplasm were significantly elevated (P < 0.05) compared with those of typical neoplastic adrenal cortical cells or the adjacent nonneoplastic zona reticularis. Ultrastructurally, cells in the myxoid component exhibited a typical adrenocortical phenotype characterized by cytoplasmic lipid vacuoles, prominent rough and smooth endoplasmic reticulum, and zonula adherens. This lesion was interpreted as an adrenal cortical carcinoma with myxoid differentiation and appeared to be highly malignant based on PCNA LI, rate of invasion into adjacent tissue, and metastasis (6/15). This report is the first description of this histologic variant in the ferret, which morphologically resembled the rare myxoid variant of adrenocortical carcinoma described in humans.


Subject(s)
Adrenal Cortex Neoplasms/veterinary , Adrenocortical Carcinoma/veterinary , Ferrets , Myxoma/veterinary , Adrenal Cortex Neoplasms/pathology , Adrenocortical Carcinoma/pathology , Animals , Biopsy , Female , Immunohistochemistry/veterinary , Inhibins/metabolism , Male , Microscopy, Electron , Myxoma/pathology , Proliferating Cell Nuclear Antigen/metabolism , Retrospective Studies , Synaptophysin/metabolism , Vimentin/metabolism
7.
Domest Anim Endocrinol ; 22(3): 169-77, 2002 May.
Article in English | MEDLINE | ID: mdl-11934525

ABSTRACT

A canine genomic library in Lambda FIX II vector was screened with a 281-base pair canine PTHrP cDNA to the prepro- and coding regions. Two genomic clones were isolated and mapped to the 3'-end of the PTHrP gene by polymerase chain reaction (PCR) amplification of exons in this region. One clone (3.5 kb) was amplified by PCR, partially sequenced, and compared to the human PTHrP gene. Regions were identified with a high degree of homology to exons 6, 7, and 8 of the human PTHrP gene. A polyadenylation site was present 3' to the exon 8-like region. Reverse transcriptase-polymerase chain reaction (RT-PCR) demonstrated that exon 7 of the PTHrP gene was transcribed in two canine carcinomas (SCC 2/88 cells and CAC-8 tumor line) which produce PTHrP. This confirmed that the 3'-region of the canine PTHrP gene is alternately spliced with splicing of exon 6 to exons 7 or 9. Transcription of exon 8 was not demonstrated by RT-PCR and suggests that the exon 8-like region of the dog PTHrP gene is not utilized. The exon 8-like region contained an early stop codon that was not present in exon 8 of the human PTHrP gene.


Subject(s)
Alternative Splicing , Cloning, Molecular , Dog Diseases/genetics , Neoplasms/veterinary , Proteins/genetics , Sequence Analysis, DNA , Adenocarcinoma/genetics , Adenocarcinoma/veterinary , Amino Acid Sequence , Animals , Apocrine Glands , Base Sequence , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/veterinary , Dogs , Gene Library , Molecular Sequence Data , Neoplasms/genetics , Parathyroid Hormone-Related Protein , Polymerase Chain Reaction , RNA, Messenger/genetics , RNA, Neoplasm/chemistry , Reverse Transcriptase Polymerase Chain Reaction , Sweat Gland Neoplasms/genetics , Sweat Gland Neoplasms/veterinary , Tumor Cells, Cultured
8.
Mol Cell Endocrinol ; 188(1-2): 37-46, 2002 Feb 25.
Article in English | MEDLINE | ID: mdl-11911944

ABSTRACT

Humoral hypercalcemia of malignancy (HHM), a paraneoplastic syndrome associated with epithelial cancers, including squamous cell carcinoma (SCC), is due to expression and secretion of parathyroid hormone-related protein (PTHrP). Transforming growth factor-beta1 (TGFbeta1), expressed by many tumors, has been demonstrated in vitro to increase the half-life of PTHrP mRNA. In this study, oral squamous carcinoma cells (SCC2/88) had a two-fold increase in PTHrP mRNA stability (from 45 to 90 min) in response to treatment with TGFbeta1. In order to examine the mechanism of TGFbeta1-mediated PTHrP mRNA stability, a cell-free assay of mRNA degradation was utilized in which the degradation of in vitro-transcribed mRNA incubated with cytoplasmic protein extracts from SCC2/88 treated with vehicle or TGFbeta1 was measured. In this assay, full-length PTHrP mRNA was not significantly stabilized in TGFbeta1-treated samples when compared to vehicle treated samples. However, there was a striking (>5-fold) increase in PTHrP mRNA half-life in TGFbeta1-treated samples when PTHrP mRNA lacked the 3'-untranslated region (3'-UTR). In contrast, the degradation of 3'-UTR-truncated PTHrP mRNA using the cell-free assay was not altered in vehicle-treated samples. UV cross-linking of PTHrP mRNA and cytoplasmic proteins from cells treated with either vehicle or TGFbeta1 revealed numerous mRNA-binding proteins. TGFbeta1 treatment resulting in decreased binding of 33, 31, 27, 20 and 18 kDa binding proteins to the terminal coding region. These studies revealed that TGFbeta1-induced PTHrP mRNA stability might be, in part, the result of cis-acting sequences within the coding region of the PTHrP mRNA.


Subject(s)
3' Untranslated Regions/metabolism , Carcinoma, Squamous Cell/metabolism , Gene Expression/drug effects , Proteins/genetics , Proteins/metabolism , RNA, Messenger/metabolism , Transforming Growth Factor beta/pharmacology , 3' Untranslated Regions/genetics , Animals , Carcinoma, Squamous Cell/drug therapy , Cell-Free System , Cross-Linking Reagents , DNA Primers/chemistry , Dichlororibofuranosylbenzimidazole/pharmacology , Dogs , Enzyme Inhibitors/pharmacology , Humans , Mouth Neoplasms/drug therapy , Mouth Neoplasms/genetics , Mouth Neoplasms/metabolism , Mutagenesis, Site-Directed , Parathyroid Hormone-Related Protein , Polymerase Chain Reaction , Protein Biosynthesis , Tumor Cells, Cultured , Ultraviolet Rays
9.
Toxicol Pathol ; 29(4): 403-10, 2001.
Article in English | MEDLINE | ID: mdl-11560244

ABSTRACT

This study assessed the effects of raloxifene, a selective estrogen receptor modulator (SERM), on ovarian morphology and circulating hormone levels in rats. Female Fischer-344 rats (65/group) were given dietary raloxifene for 6 months at average daily doses of 0, 15, 75, and 365 mg/kg. Morphologic evaluation of ovaries was conducted on 25 rats/group at the end of the treatment period and from 20 rats per group after 1 and 3 months withdrawal from treatment. Plasma hormone analyses were conducted on 10 rats pergroup at the end of the treatment period and aftereach withdrawal period. Treatment with raloxifene for 6 months resulted in disruption of the hypothalamic-pituitary-ovarian axis, manifested by increased plasma concentrations of luteinizing hormone (LH) and estradiol-17beta (E2), and failure of ovulation, manifested by ovarian follicular prominence (retained anovulatory follicles), lack of corpora lutea (CL), and depressed plasma progesterone (P4). Many (56% to 80%) rats in all raloxifene treated groups had focal, minimal to slight hyperplasia of granulosa cells within individual retained follicles. A few treated rats in the mid- and high-dose groups (2 of 25 and 3 of 25, respectively) had more extensive focal proliferation of granulosa cells. These foci were approximately 3 to 6 mm in overall size and were characterized by moderate papillary proliferation of large granulosa cells associated with cystic spaces, often with hemorrhage. In 4 of the 5 rats with this focal cystic granulosa cell hyperplasia, the remainder of the involved ovary and the contralateral ovary were atrophic. After 1 or 3 months of drug withdrawal, most previously treated rats examined had morphologic evidence of ovarian cyclic changes. including developing follicles, various stages of CL, and normal plasma levels of LH, E2, and P4. Continued lack of cyclic changes was limited to 4 of 20 rats from the low-dose group after 1 month of recovery and to 1 low dose rat after 3 months. Intrafollicular granulosa cell hyperplasia was not seen in rats in the reversibility phase. Areas of prior focal cystic granulosa cell hyperplasia were represented by focal sclerosis that included hemorrhage and/or hemosiderin. The foci of sclerosis were associated with cystic spaces after 1 month and were solid after 3 months. A granulosa cell tumor, approximately 12-13 mm diameter, was present in a high-dose rat in the 3-month reversibility group. This tumor effaced 1 ovary and was characterized by proliferative granulosa cells, usually in papillary formations and cords within cystic spaces. This rat had atrophy of the uninvolved ovary, excessive plasma levels of E2 and prolactin, and high P4 levels considering the absence of CL. The results of this study indicate that ovarian granulosa cells in rats are susceptible to proliferative changes when stimulated chronically with excessive trophic hormones. Most of these proliferative changes were reversible upon cessation of the hormonal stimulation. However, the proliferative lesion in one treated rat progressed to apparent autonomous (neoplastic) growth.


Subject(s)
Carcinogens/toxicity , Granulosa Cell Tumor/chemically induced , Granulosa Cells/pathology , Hormones/blood , Ovarian Neoplasms/chemically induced , Raloxifene Hydrochloride/toxicity , Selective Estrogen Receptor Modulators/toxicity , Animals , Dose-Response Relationship, Drug , Estradiol/blood , Female , Granulosa Cell Tumor/blood , Granulosa Cell Tumor/pathology , Granulosa Cells/drug effects , Hyperplasia , Luteinizing Hormone/blood , Ovarian Neoplasms/blood , Ovarian Neoplasms/pathology , Progesterone/blood , Rats , Rats, Inbred F344
10.
Toxicol Pathol ; 29(1): 41-8, 2001.
Article in English | MEDLINE | ID: mdl-11215683

ABSTRACT

The adrenal gland is one of the most common endocrine organs affected by chemically induced lesions. In the adrenal cortex, lesions are more frequent in the zona fasciculata and reticularis than in the zona glomerulosa. The adrenal cortex produces steroid hormones with a 17-carbon nucleus following a series of hydroxylation reactions that occur in the mitochondria and endoplasmic reticulum. Toxic agents for the adrenal cortex include short-chain aliphatic compounds, lipidosis inducers, amphiphilic compounds, natural and synthetic steroids, and chemicals that affect hydroxylation. Morphologic evaluation of cortical lesions provides insight into the sites of inhibition of steroidogenesis. The adrenal cortex response to injury is varied. Degeneration (vacuolar and granular), necrosis, and hemorrhage are common findings of acute injury. In contrast, chronic reparative processes are typically atrophy, fibrosis, and nodular hyperplasia. Chemically induced proliferative lesions are uncommon in the adrenal cortex. The adrenal medulla contains chromaffin cells (that produce epinephrine, norepinephrine, chromogranin, and neuropeptides) and ganglion cells. Proliferative lesions of the medulla are common in the rat and include diffuse or nodular hyperplasia and benign and malignant pheochromocytoma. Mechanisms of chromaffin cell proliferation in rats include excess growth hormone or prolactin, stimulation of cholinergic nerves, and diet-induced hypercalcemia. There often are species specificity and age dependence in the development of chemically induced adrenal lesions that should be considered when interpreting toxicity data.


Subject(s)
Adrenal Gland Diseases/chemically induced , Adrenal Glands/anatomy & histology , Adrenal Glands/physiology , Adrenal Gland Diseases/physiopathology , Adrenal Gland Neoplasms/pathology , Adrenal Gland Neoplasms/physiopathology , Animals , Humans
11.
Toxicol Pathol ; 29(1): 8-33, 2001.
Article in English | MEDLINE | ID: mdl-11215688

ABSTRACT

The objective of this review is to summarize the pathogenic mechanisms responsible for perturbations of endocrine function and development of structural lesions that result in important diseases in domestic and laboratory animals. For each major category, several specific disease problems have been selected to illustrate the functional and morphologic lesions that are characteristic for either a naturally occurring endocrinopathy or endocrine disturbances induced by the administration of large doses of xenobiotic chemicals. The major pathogenic mechanisms responsible for disruption of endocrine function include primary hyperfunction, secondary hyperfunction, primary hypofunction, secondary hypofunction, endocrine hyperactivity secondary to other conditions, hypersecretion of hormones by nonendocrine tumors, failure of target cells to respond to a hormone, failure of fetal endocrine function, abnormal degradation (increased or decreased rate) of hormone, and iatrogenic syndromes of hormone excess (direct and indirect). Disorders of the endocrine system are encountered in a wide variety of domestic and laboratory animal species and often present challenging diagnostic problems. The development of proliferative lesions, usually hyperplasia and benign tumors, in endocrine organs and hormone-responsive tissues are common findings in chronic studies with high doses of many nongenotoxic xenobiotic chemicals administered to sensitive rodent species and may have limited significance for human safety assessment.


Subject(s)
Endocrine Glands/pathology , Endocrine System Diseases/chemically induced , Endocrine System Diseases/pathology , Animals , Endocrine Gland Neoplasms/pathology , Humans
12.
Toxicol Pathol ; 29(6): 719-26, 2001.
Article in English | MEDLINE | ID: mdl-11794385

ABSTRACT

This study assessed the effects of raloxifene. a selective estrogen receptor modulator (SERM), on ovarian morphology and circulating hormone levels in rats. Female Fischer-344 rats (65/group) were given dietary raloxifene for 6 months at average daily doses of 0, 15, 75, and 365 mg/kg. Morphologic evaluation of ovaries was conducted on 25 rats/group at the end of the treatment period and from 20 rats per group after 1 and 3 months withdrawal from treatment. Plasma hormone analyses were conducted on 10 rats per group at the end of the treatment period and after each withdrawal period. Treatment with raloxifene for 6 months resulted in disruption of the hypothalamic-pituitary-ovarian axis, manifested by increased plasma concentrations of luteinizing hormone (LH) and estradiol-17beta (E2), and failure of ovulation, manifested by ovarian follicular prominence (retained anovulatory follicles), lack of corpora lutea (CL), and depressed plasma progesterone (P4). Many (56% to 80%) rats in all raloxifene treated groups had focal, minimal to slight hyperplasia of granulosa cells within individual retained follicles. A few treated rats in the mid- and high-dose groups (2 of 25 and 3 of 25, respectively) had more extensive focal proliferation of granulosa cells. These foci were approximately 3 to 6 mm in overall size and were characterized by moderate papillary proliferation of large granulosa cells associated with cystic spaces, often with hemorrhage. In 4 of the 5 rats with this focal cystic granulosa cell hyperplasia, the remainder of the involved ovary and the contralateral ovary were atrophic. After 1 or 3 months of drug withdrawal, most previously treated rats examined had morphologic evidence of ovarian cyclic changes, including developing follicles, various stages of CL, and normal plasma levels of LH, E2, and P4. Continued lack of cyclic changes was limited to 4 of 20 rats from the low-dose group after 1 month of recovery and to 1 low dose rat after 3 months. Intrafollicular granulosa cell hyperplasia was not seen in rats in the reversibility phase. Areas of prior focal cystic granulosa cell hyperplasia were represented by focal sclerosis that included hemorrhage and/or hemosiderin. The foci of sclerosis were associated with cystic spaces after 1 month and were solid after 3 months. A granulosa cell tumor, approximately 12-13 mm diameter, was present in a high-dose rat in the 3-month reversibility group. This tumor effaced 1 ovary and was characterized by proliferative granulosa cells, usually in papillary formations and cords within cystic spaces. This rat had atrophy of the uninvolved ovary, excessive plasma levels of E2 and prolactin, and high P4 levels considering the absence of CL. The results of this study indicate that ovarian granulosa cells in rats are susceptible to proliferative changes when stimulated chronically with excessive trophic hormones. Most of these proliferative changes were reversible upon cessation of the hormonal stimulation. However, the proliferative lesion in one treated rat progressed to apparent autonomous (neoplastic) growth.


Subject(s)
Carcinogens/toxicity , Granulosa Cell Tumor/chemically induced , Granulosa Cells/pathology , Hormones/blood , Ovarian Neoplasms/chemically induced , Raloxifene Hydrochloride/toxicity , Selective Estrogen Receptor Modulators/toxicity , Animals , Dose-Response Relationship, Drug , Estradiol/blood , Female , Granulosa Cell Tumor/blood , Granulosa Cell Tumor/pathology , Granulosa Cells/drug effects , Hyperplasia , Luteinizing Hormone/blood , Ovarian Neoplasms/blood , Ovarian Neoplasms/pathology , Progesterone/blood , Rats , Rats, Inbred F344
13.
Anticancer Res ; 21(5): 3355-63, 2001.
Article in English | MEDLINE | ID: mdl-11848494

ABSTRACT

BACKGROUND: We investigated the effects of 1,25(OH)2D3 and selected analogs on canine squamous carcinoma cells (SCC 2/88) and tested whether these compounds could effectively decrease proliferation, induce differentiation, and inhibit PTHrP production and PTHrP mRNA expression. MATERIALS AND METHODS: SCC 2/88 cells were cultured and treated with three substrates. The media were collected for PTHrP immunoradiometric assay. The cells were analyzed for DNA concentration and PTHrP mRNA expression by Northern blot analysis, involucrin by Western blot analysis and 1,25(OH)2D3-receptor (VDR) and PTHrP by immunohistochemistry. RESULTS: The SCC 2/88 cells were stained positively for VDR and PTHrP by immunohistochemistry. 1,25(OH)2D3 and its analogs inhibited cell growth and stimulated differentiation in a dose-dependent manner. All three substrate-treated groups had significantly increased PTHrP secretion at 10(-7) M. Cells treated with 1,25(OH)2D3 at 10(-7) M had 2- to 4-fold increased PTHrP mRNA expression at 12 and 24 hours compared to the vehicle-treated controL PTHrP mRNA in cells treated with TGF-beta (1.5 ng/ml) was increased 7- to 17-fold at 6, 12 and 24 hours compared to the vehicle-treated controL PTHrP mRNA expression was reduced by 0.5- to 2-fold in cells treated with 1,25(OH)2D3 at 10(-7) M and TGF-beta (1.5 ng/ml) together compared to cells treated with TGF-beta alone. CONCLUSION: 1,25(OH)2D3, EB1089, and analog V inhibited SCC 2/88 growth and induced differentiation in a dose-dependent manner, but did not inhibit PTHrP production. 1,25(OH)2D3 treatment led to increased PTHrP mRNA expression and reduced the stimulatory effect of TGF-beta on PTHrP mRNA expression in SCC 2/88 cells.


Subject(s)
Antineoplastic Agents/pharmacology , Calcitriol/analogs & derivatives , Protein Biosynthesis , Animals , Calcitriol/pharmacology , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/pathology , Cell Differentiation/drug effects , Cell Division/drug effects , Cell Division/physiology , Dogs , Immunohistochemistry , Parathyroid Hormone-Related Protein , Proteins/antagonists & inhibitors , Proteins/genetics , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Receptors, Calcitriol/biosynthesis , Transforming Growth Factor beta/biosynthesis , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/pharmacology
14.
Otolaryngol Head Neck Surg ; 123(5): 558-62, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11077340

ABSTRACT

OBJECTIVES: Parathyroid hormone-related protein (PTHrP) is expressed by squamous cell carcinomas. Our first objective was to examine the stability of PTHrP in normal human plasma. Our second objective was to determine whether plasma PTHrP could be used in patients with head and neck squamous cell carcinoma (HNSCC) as an indicator of tumor burden or relapse. STUDY DESIGN AND SETTING: Blood and urine samples from 55 HNSCC patients undergoing tumor resection at The Ohio State University were measured for plasma PTHrP (1-86) concentration, serum ionized calcium concentration, and urine calcium/creatinine ratio. RESULTS: Two of 55 HNSCC patients had detectable levels of plasma PTHrP. Serum ionized calcium concentrations and urinary calcium/creatinine ratios were within normal limits in all patients. CONCLUSIONS: Plasma PTHrP was not a valuable indicator of tumor presence or recurrence in our patient population. SIGNIFICANCE: Plasma PTHrP is not a useful marker of tumor presence or recurrence in patients with stage II to IV or recurrent HNSCC.


Subject(s)
Biomarkers, Tumor/blood , Calcium/blood , Calcium/urine , Carcinoma, Squamous Cell/blood , Head and Neck Neoplasms/blood , Neoplasm Proteins/blood , Proteins/analysis , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Parathyroid Hormone-Related Protein , Recombinant Proteins/blood
15.
Internet resource in English | LIS -Health Information Locator | ID: lis-2831

ABSTRACT

It examines the scientific basis for possible species differences in mechanisms by which thyroid follicular-cell tumours in mice and rats, renal tubule-cell tumours in male rats and urinary bladder tumours in rats may be produced.


Subject(s)
Kidney Neoplasms/etiology , Urologic Neoplasms/etiology , Rats , Animals, Laboratory , Toxicology , Medical Oncology
16.
Am J Pathol ; 157(2): 671-7, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10934169

ABSTRACT

Papillary thyroid carcinomas in humans are associated with the ret/PTC oncogene and, following loss of p53 function, may progress to anaplastic carcinomas. Mice with thyroid-targeted expression of ret/PTC1 developed papillary thyroid carcinomas that were minimally invasive and did not metastasize. These mice were crossed with p53-/- mice to investigate whether loss of p53 would promote anaplasia and metastasis of ret/PTC1-induced thyroid tumors. The majority of p53-/- mice died or were euthanized by 17 weeks of age due to the development of thymic lymphomas, soft tissue sarcomas, and testicular teratomas. All ret/PTC1 mice developed thyroid carcinomas, but tumors in p53-/- mice were more anaplastic, larger in diameter, more invasive, and had a higher mitotic index than tumors in p53+/+ and p53+/- mice. Thyroid tumors did not metastasize in any of the experimental p53+/+ and p53+/- mice

Subject(s)
Oncogene Proteins, Fusion/genetics , Thyroid Gland/metabolism , Thyroid Neoplasms/genetics , Tumor Suppressor Protein p53/genetics , Anaplasia , Animals , Disease Models, Animal , Female , Genotype , Humans , Lung Neoplasms/secondary , Male , Mice , Mice, Inbred Strains , Mice, Knockout , Mitotic Index , Neoplasm Invasiveness , Neoplasm Metastasis , Protein-Tyrosine Kinases , Thyroid Gland/pathology , Thyroid Neoplasms/mortality , Thyroid Neoplasms/pathology , Time Factors
17.
Regul Toxicol Pharmacol ; 30(1): 9-17, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10464042

ABSTRACT

Subchronic/chronic toxicity studies on antimony potassium tartrate (APT) have been reviewed. One of the older studies (H. A. Schroeder et al., 1970, J. Nutr. 100 (1), 59-68), on which are based the EPA reference dose value and a number of state, national, and international drinking water criteria for antimony, has severe inadequacies in study conduct making it uninterpretable and inappropriate for characterization of APT toxicity. In particular, the manner in which control data were generated and utilized in this study is considered invalid. More recent drinking water studies conducted by the NTP (1992, "NTP Technical Report on Toxicity Studies of Antimony Potassium Tartrate in F344/N Rats and B6C3F(1) Mice (Drinking Water and Intraperitoneal Injection Studies)," NTP Toxicity Report Series, No. 11) and Poon et al. (1998, Food Chem. Toxicol. 36, 20-35) showed antimony to be of low toxicity. The NOAEL in the 14-day NTP study was 2500 ppm by the oral route in both rats and mice, while Poon et al. (1998) suggested a NOAEL of 0.5 ppm in their 90-day study. However, upon close examination, it was determined that this value was based on subtle histological changes in the thyroid gland that were physiological, not toxicological, in nature. This conclusion is supported further by an absence of these changes in a well-conducted 13-week intraperitoneal exposure study in rats that utilized APT at much higher doses (NTP, 1992). Thus, the NOAEL by Poon et al. (1998) should more appropriately be 50 ppm. When regulatory criteria for antimony are established and/or reviewed, the findings in the NTP study and this critical reevaluation of the Poon et al. (1998) study should be considered when establishing a NOAEL for subchronic exposure to antimony in the future.


Subject(s)
Antimony Potassium Tartrate/toxicity , Schistosomicides/toxicity , Animals , Humans , No-Observed-Adverse-Effect Level
18.
Mol Cell Endocrinol ; 152(1-2): 189-97, 1999 Jun 25.
Article in English | MEDLINE | ID: mdl-10432236

ABSTRACT

Parathyroid hormone-related protein (PTHrP), an important factor in the pathogenesis of humoral hypercalcemia of malignancy, is produced by many normal tissues, including the skin, where it regulates keratinocyte growth and differentiation and dermal fibroblast function. Keratinocyte growth factor (KGF), a member of the fibroblast growth factor (FGF) family, is a secretory product of stromal cells and functions as a mediator of epithelial cell growth and differentiation. Phenotypes of the skin in several transgenic mouse models, in which the KGF and PTHrP genes have been overexpressed or disrupted, suggest that these two factors interact in vivo to regulate homeostasis of the skin. In this study, we investigated the effects of KGF on PTHrP secretion and expression by normal human foreskin keratinocytes (NHFK) and the effects of PTHrP on KGF secretion and expression by normal human dermal fibroblasts (NHDF) in vitro. N-terminal PTHrP(1-36) increased KGF secretion, protein expression and mRNA expression by NHDF in a dose-dependent manner, however, KGF did not regulate PTHrP expression and secretion by NHFK. By flow cytometry, PTHrP also increased the percentage of NHDF producing KGF. Our results indicate that PTHrP produced by keratinocytes is a potential paracrine regulator of KGF expression by dermal fibroblasts in vivo. This paracrine regulation may explain, in part, the epidermal atrophy seen in the PTHrP null mice and epidermal hyperplasia seen in transgenic mice overexpressing PTHrP in their basal keratinocytes. Our results also suggest that PTHrP is an important mediator for the healing of skin wounds and growth of neoplasms of squamous origin.


Subject(s)
Fibroblast Growth Factors , Fibroblasts/metabolism , Growth Substances/metabolism , Keratinocytes/cytology , Keratinocytes/metabolism , Proteins/metabolism , Animals , Cell Division , Cells, Cultured , Fibroblast Growth Factor 10 , Fibroblast Growth Factor 7 , Humans , Interleukin-1/pharmacology , Mice , Parathyroid Hormone-Related Protein , Peptide Fragments/pharmacology , Proteins/pharmacology , Skin/cytology , Skin/metabolism
19.
Oncogene ; 18(24): 3659-65, 1999 Jun 17.
Article in English | MEDLINE | ID: mdl-10380889

ABSTRACT

The RET/PTC1 oncogene, a rearranged form of the RET proto-oncogene, has been reported to be associated with human papillary thyroid carcinomas. We have shown that targeted expression of RET/PTC1 in the thyroid gland leads to the development of thyroid carcinomas in transgenic mice with histologic and cytologic similarities to human papillary thyroid carcinoma. To further investigate how RET/PTC1 expression contributes to the pathogenesis of papillary thyroid tumor, the time of tumor onset and the early phenotypic consequences of RET/PTC1 expression in thyrocytes were determined. All high copy transgenic mice developed bilateral thyroid tumors as early as 4 days of age. At embryological days 16-18, increased proliferation rate, distorted thyroid follicle formation and reduced radioiodide concentrating activity were identified in transgenic embryos. The reduced radioiodide concentrating activity was attributed to decreased expression of the sodium-iodide symporter. Our study showed that RET/PTC1 not only increased proliferation of thyrocytes, it also altered morphogenesis and differentiation. These findings provide a model for the role of RET/PTC1 in the formation of abnormal follicles with reduced iodide uptake ability observed in human papillary thyroid carcinoma.


Subject(s)
Oncogene Proteins, Fusion/genetics , Oncogenes , Symporters , Thyroid Gland/metabolism , Thyroid Neoplasms/pathology , Age of Onset , Animals , Carrier Proteins/genetics , Cell Division , Congenital Hypothyroidism , DNA/biosynthesis , Disease Progression , Embryo, Mammalian/metabolism , Embryo, Mammalian/pathology , Gene Expression , Hypothyroidism/genetics , Hypothyroidism/metabolism , Iodine Radioisotopes/metabolism , Membrane Proteins/genetics , Mice , Mice, Transgenic , Morphogenesis , Phenotype , Protein-Tyrosine Kinases , Proto-Oncogene Mas , RNA, Messenger/genetics , RNA, Messenger/metabolism , Thyroid Gland/drug effects , Thyroid Gland/embryology , Thyroid Gland/pathology , Thyroid Neoplasms/embryology , Thyroid Neoplasms/genetics , Thyroid Neoplasms/metabolism , Thyrotropin/pharmacology , Thyroxine/pharmacology
20.
Prostate ; 39(3): 187-97, 1999 May 15.
Article in English | MEDLINE | ID: mdl-10334108

ABSTRACT

BACKGROUND: Prostate cancer frequently metastasizes to bone, where it induces osteoblastic lesions. Parathyroid hormone-related protein (PTHrP), a product of normal and neoplastic prostate cells, may promote growth and bone metastasis of certain types of cancer. In this study, we investigated the: 1) pathogenesis and morphology of bone metastases in the MATLyLu rat prostate adenocarcinoma model, and 2) effect of PTHrP overexpression on tumor growth and incidence of bone metastasis. METHODS: MATLyLu cells were stably transfected with a PTHrP expression vector or control plasmid. PTHrP expression was determined in vitro by immunoradiometric assay and Northern blot analysis. MATLyLu cells were injected into the left ventricle of Copenhagen rats to induce bone metastases. Histology and radiography were used to quantify the size and number of bone metastases. Serum alkaline phosphatase isoenzyme concentrations and histomorphometric analysis were used to evaluate bone formation and resorption. RESULTS: All rats developed osteolytic metastases in long bones and vertebrae. There was no evidence of increased intramedullary bone formation. PTHrP overexpression by MATLyLu cells was not associated with any difference in the incidence of bone metastasis, size of metastatic foci or tumor-cell proliferation. CONCLUSIONS: The MATLyLu intracardiac injection model of prostate carcinoma is an aggressive tumor model with a high incidence of osteolytic skeletal metastases, and is not altered by increased PTHrP production by neoplastic prostate epithelial cells.


Subject(s)
Adenocarcinoma/secondary , Bone Neoplasms/secondary , Prostatic Neoplasms/pathology , Protein Biosynthesis , Adenocarcinoma/metabolism , Alkaline Phosphatase/blood , Animals , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/epidemiology , Bone Neoplasms/metabolism , Calcium/blood , Cell Division , Disease Models, Animal , Incidence , Isoenzymes/blood , Male , Neoplasm Metastasis , Neoplasm Transplantation , Parathyroid Hormone-Related Protein , Prostatic Neoplasms/metabolism , Proteins/genetics , RNA, Messenger/biosynthesis , Radiography , Rats , Transfection , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...